Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC

Tianhong Li, Weijie Ma, Eddie C. Tian

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

ASJC Scopus subject areas

@article{cb7a6c3edbe04bdd8c427fd81541a9d5,

title = "Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC",

author = "Tianhong Li and Weijie Ma and Tian, {Eddie C.}",

year = "2019",

month = oct,

day = "1",

doi = "10.21037/cco.2018.10.12",

language = "English (US)",

volume = "8",

pages = "S4",

journal = "Chinese Clinical Oncology",

issn = "2304-3865",

publisher = "Society for Translational Medicine (STM)",

number = "S1",

}

TY - JOUR

T1 - Ensartinib (X-396)

T2 - what does it add for patients with ALK-rearranged NSCLC

AU - Li, Tianhong

AU - Ma, Weijie

AU - Tian, Eddie C.

PY - 2019/10/1

Y1 - 2019/10/1

UR - http://www.scopus.com/inward/record.url?scp=85067464605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067464605&partnerID=8YFLogxK

U2 - 10.21037/cco.2018.10.12

DO - 10.21037/cco.2018.10.12

M3 - Article

C2 - 30525756

AN - SCOPUS:85067464605

VL - 8

SP - S4

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - S1

ER -